Sie befinden sich hier

Inhalt

Publications and Theses

Velásquez, S. Y., Baslar, G. E., Schulte, J., Fuderer, T., Lindner, H. A., & Coulibaly, A. (2024).
Downregulation of hypoxia inducible factor-1α in primary human natural killer cells using small interfering RNA delivery with ExPERT ATx by MaxCyte.
Current Protocols, 4, e987. doi: 10.1002/cpz1.987

Yu Y, Farooq MS, Eberhart Meessen S, Jiang Y, Kato D, Zhan T, Weiss C, Seger R, Kang W, Zhang X, Yu J, Ebert MPA, Burgermeister E.
Nuclear pore protein POM121 regulates subcellular localization and transcriptional activity of PPARγ.
Cell Death Dis. 2024 Jan 4;15(1):7. doi: 10.1038/s41419-023-06371-1.

Burgermeister E.
Mitogen-Activated Protein Kinase and Nuclear Hormone Receptor Crosstalk in Cancer Immunotherapy.
Int J Mol Sci. 2023 Sep 4;24(17):13661. doi: 10.3390/ijms241713661

Burgermeister E.
Mitogen-Activated Protein Kinase and Exploratory Nuclear Receptor Crosstalk in Cancer Immunotherapy.
Int J Mol Sci. 2023 Sep 26;24(19):14546. doi: 10.3390/ijms241914546.

Thomann AK, Wüstenberg T, Wirbel J, Knoedler LL, Thomann PA, Zeller G, Ebert MP, Lis S, Reindl W.
Depression and fatigue in active IBD from a microbiome perspective-a Bayesian approach to faecal metagenomics.
BMC Med. 2022 Oct 17;20(1):366. doi: 10.1186/s12916-022-02550-7.

Hinsenkamp I, Köhler JP, Flächsenhaar C, Hitkova I, Meessen SE, Gaiser T, Wieland T, Weiss C, Röcken C, Mowat M, Quante M, Taxauer K, Mejias-Luque R, Gerhard M, Vogelmann R, Meindl-Beinker N, Ebert M, Burgermeister E.
Functional antagonism between CagA and DLC1 in gastric cancer.
Cell Death Discov. 2022 Aug 13;8(1):358. doi: 10.1038/s41420-022-01134-x.

Ebert MP, Meindl-Beinker NM, Gutting T, Maenz M, Betge J, Schulte N, Zhan T, Weidner P, Burgermeister E, Hofheinz R, Vogel A, Angermeier S, Bolling C, de Wit M, Jakobs R, Karthaus M, Stocker G, Thuss-Patience P, Leidig T, Gaiser T, Kather JN, Haertel N.
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial.
Lancet Healthy Longev. 2022 Jun;3(6):e417-e427. doi: 10.1016/S2666-7568(22)00116-7.

Betge J, Rindtorff N, Sauer J, Rauscher B, Dingert C, Gaitantzi H, Herweck F, Srour-Mhanna K, Miersch T, Valentini E, Boonekamp KE, Hauber V, Gutting T, Frank L, Belle S, Gaiser T, Buchholz I, Jesenofsky R, Härtel N, Zhan T, Fischer B, Breitkopf-Heinlein K, Burgermeister E, Ebert MP, Boutros M.
The drug-induced phenotypic landscape of colorectal cancer organoids.
Nat Commun. 2022 Jun 6;13(1):3135. doi: 10.1038/s41467-022-30722-9.

Lerma-Martin C, Badia-i-Mompel P, Ramirez Flores RO, Sekol P, Hofmann A, Thäwel T, Riedl CJ, Wünnemann F, Ibarra-Arellano MA, Trobisch T, Eisele P, Schapiro D, Haeussler M, Hametner S, Saez-Rodriguez J, Schirmer L.
Spatial cell type mapping of multiple sclerosis lesions.
bioRxiv preprint. 2022 Nov 3. doi: 10.1101/2022.11.03.514906

Kontextspalte

GRK 2727/1 InCheck
„Innate Immune Checkpoints in Cancer and Tissue Damage"

TPMA2, 2. OG
Franz-Volhard-Str. 6
68167 Mannheim

Phone +49 621 383-71509
Fax +49 621 383-71506
grk2727@remove-this.medma.uni-heidelberg.de
Twitter GRK 2727: @grk2727